Aptamers Against COVID-19: An Untested Opportunity

Overview

Journal Mini Rev Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2022 Jan 13

PMID 35023454

Authors

Annekathrin Haberland

Johannes Muller

Affiliations

Soon will be listed here.

Abstract

Given the lack of success in the development of effective drugs to treat COVID-19, which show "game-changing" potential, it is necessary to explore drugs with different modes of action. Single mode-of-action drugs have not been succeeded in curing COVID-19, which is a highly complex disease. This is the case for direct antivirals and anti-inflammatory drugs, both of which treat different phases of the disease. Aptamers are molecules that deliver different modes of action, allowing their effects to be bundled, which, when combined, support their therapeutic efficacy. In this minireview, we summarise the current activities in the development of aptamers for the treatment of COVID-19 and long-COVID. A special emphasis is placed on the capability of their multiple modes of action, which is a promising approach for treating complex diseases such as COVID-19.

Citing Articles

After the Hurricane: Anti-COVID-19 Drugs Development, Molecular Mechanisms of Action and Future Perspectives.

Khalifa H, Al Ramahi Y Int J Mol Sci. 2024; 25(2).

PMID: 38255813 PMC: 10815681. DOI: 10.3390/ijms25020739.

Highly efficacious and safe neutralizing DNA aptamer of SARS-CoV-2 as an emerging therapy for COVID-19 disease.

Ayass M, Tripathi T, Griko N, Pashkov V, Dai J, Zhang J Virol J. 2022; 19(1):227.

PMID: 36581924 PMC: 9800238. DOI: 10.1186/s12985-022-01943-7.

References

Musafia B, Oren-Banaroya R, Noiman S . Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptamer-virus interaction. PLoS One. 2014; 9(5):e97696. PMC: 4028238. DOI: 10.1371/journal.pone.0097696. View

Bala J, Chinnapaiyan S, Kumar Dutta R, Unwalla H . Aptamers in HIV research diagnosis and therapy. RNA Biol. 2018; 15(3):327-337. PMC: 5927724. DOI: 10.1080/15476286.2017.1414131. View

Kruger A, de Jesus Santos A, De Sa V, Ulrich H, Wrenger C . Aptamer Applications in Emerging Viral Diseases. Pharmaceuticals (Basel). 2021; 14(7). PMC: 8308861. DOI: 10.3390/ph14070622. View

Hu F, Chen F, Ou Z, Fan Q, Tan X, Wang Y . A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell Mol Immunol. 2020; 17(11):1119-1125. PMC: 7546387. DOI: 10.1038/s41423-020-00550-2. View

Salway R, Silvestri D, Wei E, Bouton M . Using Information Technology To Improve COVID-19 Care At New York City Health + Hospitals. Health Aff (Millwood). 2020; 39(9):1601-1604. DOI: 10.1377/hlthaff.2020.00930. View

Jang K, Lee N, Yeo W, Jeong Y, Kim D . Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Biochem Biophys Res Commun. 2007; 366(3):738-44. PMC: 7092905. DOI: 10.1016/j.bbrc.2007.12.020. View

Shabalin I, Czub M, Majorek K, Brzezinski D, Grabowski M, Cooper D . Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy. IUCrJ. 2020; 7(Pt 6). PMC: 7553145. DOI: 10.1107/S2052252520012944. View

Pardi N, Hogan M, Porter F, Weissman D . mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4):261-279. PMC: 5906799. DOI: 10.1038/nrd.2017.243. View

Talasaz A, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, Kordzadeh-Kermani E, Van Tassell B . Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021; 77(15):1903-1921. PMC: 7963001. DOI: 10.1016/j.jacc.2021.02.035. View

10.

Schultze P, Macaya R, Feigon J . Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J Mol Biol. 1994; 235(5):1532-47. DOI: 10.1006/jmbi.1994.1105. View

11.

Kim T, Lee S . Aptamers for Anti-Viral Therapeutics and Diagnostics. Int J Mol Sci. 2021; 22(8). PMC: 8074132. DOI: 10.3390/ijms22084168. View

12.

Wang E, Mao T, Klein J, Dai Y, Huck J, Jaycox J . Diverse functional autoantibodies in patients with COVID-19. Nature. 2021; 595(7866):283-288. DOI: 10.1038/s41586-021-03631-y. View

13.

Marchand C, Maddali K, Metifiot M, Pommier Y . HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem. 2009; 9(11):1016-37. PMC: 2860603. DOI: 10.2174/156802609789630910. View

14.

Sun M, Liu S, Wei X, Wan S, Huang M, Song T . Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. Angew Chem Int Ed Engl. 2021; 60(18):10266-10272. PMC: 8014204. DOI: 10.1002/anie.202100225. View

15.

Shum K, Tanner J . Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase. Chembiochem. 2008; 9(18):3037-45. PMC: 7161993. DOI: 10.1002/cbic.200800491. View

16.

Zhou G, Wilson G, Hebbard L, Duan W, Liddle C, George J . Aptamers: A promising chemical antibody for cancer therapy. Oncotarget. 2016; 7(12):13446-63. PMC: 4924653. DOI: 10.18632/oncotarget.7178. View

17.

Haberland A, Holtzhauer M, Schlichtiger A, Bartel S, Schimke I, Muller J . Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors. Eur J Pharmacol. 2016; 789:37-45. DOI: 10.1016/j.ejphar.2016.06.061. View

18.

Xiao X, Li H, Zhao L, Zhang Y, Liu Z . Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications. Biomed Pharmacother. 2021; 143:112232. DOI: 10.1016/j.biopha.2021.112232. View

19.

Girvan A, Teng Y, Casson L, Thomas S, Juliger S, Ball M . AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther. 2006; 5(7):1790-9. DOI: 10.1158/1535-7163.MCT-05-0361. View

20.

Torabi R, Ranjbar R, Halaji M, Heiat M . Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review. Mol Cell Probes. 2020; 53:101636. PMC: 7334654. DOI: 10.1016/j.mcp.2020.101636. View